Methylated Folate (L-Methylfolate) and MTHFR

By RRM Academy Reviewed by Dr. Naomi Whittaker, MD, Board-Certified OBGYN, MIGS, NFPMC, FCI Updated July 27, 2026

Methylated folate (L-methylfolate, or 5-methyltetrahydrofolate) is the biologically active form of folate that cells use directly for methylation reactions, without needing the MTHFR-dependent conversion step to produce it. Most prenatal vitamins and fortified foods supply synthetic folic acid, which the enzyme dihydrofolate reductase reduces first to dihydrofolate, then to tetrahydrofolate, the form cells use for most folate-dependent reactions, including DNA synthesis. MTHFR acts further downstream, converting 5,10-methylenetetrahydrofolate, a derivative of that tetrahydrofolate, into 5-methyltetrahydrofolate (5-MTHF), the specific methyl donor used to remethylate homocysteine back to methionine. The two common MTHFR variants, C677T and A1298C, do not carry equal weight. C677T homozygosity reduces MTHFR enzyme activity substantially and raises homocysteine, particularly when folate intake is low. A1298C alone has a milder effect, and current evidence does not support that it meaningfully alters folate handling on its own; A1298C matters most in compound heterozygotes, carriers of one C677T allele and one A1298C allele together. Either way, reduced MTHFR activity narrows the methylation step specifically. It does not block the earlier, DHFR-driven conversion of folic acid to tetrahydrofolate: reduced MTHFR activity constrains the methylation arm of folate metabolism, not the ability to use folic acid at all.

When MTHFR activity is meaningfully reduced, the methylation and homocysteine remethylation cycle runs less efficiently. One consequence is elevated homocysteine, a byproduct that rises when remethylation is impaired. Elevated homocysteine carries both thrombophilic properties and potential embryotoxic effects. This links MTHFR variants to recurrent pregnancy loss and to the broader category of autoimmune and thrombophilic disorders evaluated in RPL workups.¹

L-methylfolate bypasses the MTHFR conversion step entirely. Because it is already in the active methyl-donor form, cells can use it for remethylation regardless of MTHFR efficiency. For carriers of reduced-activity MTHFR variants, who may not complete this final methylation step efficiently, L-methylfolate supplementation supplies the active form directly rather than depending on MTHFR to produce it. The preconception period and early pregnancy are when folate-dependent processes, including DNA synthesis and neural tube development, are most active.

MTHFR variants are common across the general population, far more so than rare thrombophilias like Factor V Leiden. Most carriers have never been tested. Homocysteine and folate status are the functional measures that answer the clinical question: whether methylation capacity is adequate. Genotype alone does not drive management. Related: thrombophilia, antiphospholipid syndrome.

This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.